Bladder Cancer

Both the death rate and incidence rate for prostate cancer continues to decline, according to the latest round of statistics from leading U.S. cancer groups.

Urology drugs and devices in the pipeline from AltheRx Pharmaceuticals, TARIS Biomedical, AstraZeneca, NxThera, NovaBay Pharmaceuticals, and OncoGenex Pharmaceuticals.

Standard and reduced high-dose volume radiation therapy for muscle-invasive bladder cancer provide similar tumor control and decreased late toxicity when compared to surgery, say the authors of a study from the United Kingdom.

The latest products and services from Cook Medical, American Medical Systems, Dialog Medical, Astellas Pharma U.S., Giffen Solutions, the Société Internationale d’Urologie, Merck Consumer Care, and the Bladder Cancer Advocacy Network.

Drugs and devices in the pipeline from Targacept, Inc., Cubist, OncoGenex Pharmaceuticals, Inc., Apricus Biosciences, and Nymox Pharmaceutical Corp.

British researchers have developed a device that they say is able to read odors in urine to help diagnose patients with early signs of bladder cancer.

Danil V. Makarov, MD, MHS, presents the take home messages on outcomes analysis.

Edmund Chiong, MD, presents the take home messages on bladder cancer from the AUA annual meeting in San Diego.

More intense surveillance and treatment in the first 2 years after a bladder cancer diagnosis could reduce the number of patients whose cancer recurs and lower the death rate from this disease, according to researchers from UCLA’s Jonsson Comprehensive Cancer Center.

MicroRNA expression appears to serve as a biomarker for predicting the progression of bladder urothelial carcinoma, the authors of a study from Israel reported.

Two recent studies appear to shed light on the effect of smoking on bladder cancer outcomes and the role a certain protein plays in metastatic disease.

Hospital volume is a key predictor of survival for patients with urothelial bladder cancer undergoing radical cystectomy and has a greater impact than surgeon volume, findings from a retrospective analysis suggest.

In patients with stage pT1 urothelial bladder cancer, intravesical bacillus Calmette-Guérin (TheraCys, TICE BCG) combined with electromotive mitomycin-C produces higher remission rates and longer remission times than BCG alone, Italian researchers reported.